Home › Compare › ARAV vs JEPQ

ARAV vs JEPQ: Dividend Comparison 2026

ARAV yields 4987.53% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARAV wins by $60726414423802.55M in total portfolio value
10 years
ARAV
ARAV
● Live price
4987.53%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$60726414423802.59M
Annual income
$58,422,163,401,288,310,000.00
Full ARAV calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — ARAV vs JEPQ

📍 ARAV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARAVJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARAV + JEPQ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ARAV pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARAV
Annual income on $10K today (after 15% tax)
$423,940.15/yr
After 10yr DRIP, annual income (after tax)
$49,658,838,891,095,065,000.00/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, ARAV beats the other by $49,658,838,891,095,065,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARAV + JEPQ for your $10,000?

ARAV: 50%JEPQ: 50%
100% JEPQ50/50100% ARAV
Portfolio after 10yr
$30363207211901.31M
Annual income
$29,211,081,700,644,155,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARAV right now

ARAV
Analyst Ratings
8
Buy
9
Hold
1
Sell
Consensus: Hold
Price Target
$0.25
+523.4% upside vs current
Range: $0.25 — $0.25
Altman Z
-90.4
Piotroski
4/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARAV buys
0
JEPQ buys
0
No recent congressional trades found for ARAV or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARAVJEPQ
Forward yield4987.53% ✓11.10%
Annual dividend / share$2.00$6.16 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$60726414423802.59M ✓$44.8K
Annual income after 10y$58,422,163,401,288,310,000.00 ✓$2,152.59
Total dividends collected$60570499970588.68M ✓$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ARAV vs JEPQ ($10,000, DRIP)

YearARAV PortfolioARAV Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$509,453$498,753.12$11,930$1,110.39+$497.5K → ARAV
2$24,291,968$23,746,853.30$14,133$1,224.34+$24.28M → ARAV
3$1,084,224,114$1,058,231,708.37$16,632$1,340.46+$1084.21M → ARAV
4$45,302,256,588$44,142,136,785.73$19,454$1,457.97+$45302.24M → ARAV
5$1,772,207,810,855$1,723,734,396,305.83$22,626$1,576.08+$1772207.79M → ARAV
6$64,916,695,091,411$63,020,432,733,796.11$26,175$1,694.09+$64916695.07M → ARAV
7$2,226,904,004,397,647$2,157,443,140,649,837.00$30,133$1,811.32+$2226904004.37M → ARAV
8$71,550,063,790,460,920$69,167,276,505,755,440.00$34,531$1,927.17+$71550063790.43M → ARAV
9$2,153,505,628,518,013,700$2,076,947,060,262,220,500.00$39,403$2,041.08+$2153505628517.97M → ARAV
10$60,726,414,423,802,585,000$58,422,163,401,288,310,000.00$44,787$2,152.59+$60726414423802.55M → ARAV

ARAV vs JEPQ: Complete Analysis 2026

ARAV — Stock

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Full ARAV Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this ARAV vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARAV vs SCHDARAV vs JEPIARAV vs OARAV vs KOARAV vs MAINARAV vs XYLDARAV vs QYLDARAV vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.